Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 156
2 55
1 24
NEB 4
Curative setting
A 54
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 21
Gastrointestinal Cancers 76
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pembrolizumab - Cisplatin or carboplatin/5-FU/cetuximab As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥20 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Cisplatin or carboplatin/5-FU Cisplatin or carboplatin/5-FU/cetuximab In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab - Standard of care (methotrexate, docetaxel or cetuximab) Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing ChT KEYNOTE-040
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-040

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Sunitinib - Placebo EMA: Sunitinib is indicated for the ttreatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. FDA: Sunitinib for the treatment of patients with metastatic and/or unresectable GIST whose disease has progressed despite at least imatinib as prior treatments. A6181004
    Sarcoma
    		 GIST - A6181004

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Regorafenib Best supportive care Placebo plus best supportive care Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. GRID
    Sarcoma
    		 GIST - GRID

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Placebo Previously treated non-GIST metastatic soft tissue sarcoma PALETTE
    Sarcoma
    		 Soft tissue - PALETTE

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Eribulin - Dacarbazine Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease
    Sarcoma
    		 Soft tissue - Liposarcoma or leiomyosarcoma - -

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Imatinib 1-year - Placebo Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry ACOSOG Z9001
    Sarcoma
    		 GIST KIT+ ACOSOG Z9001

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Imatinib 3-years - Imatinib 1-year Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. SSG XVIII
    Sarcoma
    		 GIST KIT+ SSG XVIII

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Olaparib - Placebo Maintenance treatment of adult patients with gBRCAm who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line ChT regimen POLO
    Gastrointestinal Cancers
    		 Pancreatic cancer gBRCAm POLO

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Entrectinib - Single arm trials (Phase I/II) Treatment of adult and paediatric patients older than 1 month with solid tumours that have NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options. STARTRK-1; STARTRK-2; ALKA-372-001
    Tumour agnostic
    		 - NTRK gene fusion STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Entrectinib - Single arm Treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors STARTRK-1; STARTRK-2; ALKA-372-001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer Refractory NTRK fusion–positive cancers STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Avapritinib - Single arm Treatment of adult patients with unresectable or metastatic GIST harbouring the platelet-derived growth factor receptor alpha D842V mutation NAVIGATOR
    Sarcoma
    		 GIST PDGFRA D842V-mutant NAVIGATOR

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Durvalumab Etoposide and either carboplatin or cisplatin Platinum-etoposide First-line treatment of extensive-stage SCLC CASPIAN
    Thoracic Malignancies
    		 Small-cell lung cancer - CASPIAN

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Brigatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor ALTA-1L
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALTA-1L

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Niraparib - Placebo Maintenance treatment for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT PRIMA/ENGOT-OV26/COG-3012
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer - PRIMA/ENGOT-OV26/COG-3012

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Atezolizumab Bevacizumab Sorafenib Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy IMbrave150
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - IMbrave150

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Olaparib - Enzalutamide or abiraterone (crossover allowed) Treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent PROfound
    Genitourinary Cancers
    		 Prostate cancer Patients with ≥1 alteration in BRCA1, BRCA2 or ATM PROfound

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Olaparib Bevacizumab Placebo + bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer HRD+, BRCA-mut PAOLA-1

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Selpercatinib - Single arm Treatment of adults with RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib LIBRETTO-001 (Cohort 1)
    Endocrine Tumours
    		 Thyroid cancer - differentiated RET fusion-positive LIBRETTO-001 (Cohort 1)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Encorafenib Cetuximab Either irinotecan or FOLFIRI with cetuximab Treatment of patients with mCRC with a BRAF V600E mutation, who have received prior systemic therapy BEACON CRC
    Gastrointestinal Cancers
    		 Colorectal Cancer BRAF V600E BEACON CRC

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Avelumab Best supportive care Best supportive care First-line maintenance treatment of adult patients who are progression-free following platinum-based ChT JAVELIN Bladder 100
    Genitourinary Cancers
    		 Urothelial Carcinoma - JAVELIN Bladder 100

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Lurbinectedin - Single arm Metastatic SCLC with disease progression on or after platinum-based ChT PM1183-B-005-14
    Thoracic Malignancies
    		 Small-cell lung cancer - PM1183-B-005-14

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Nivolumab + ipilimumab - Chemotherapy First-line treatment for patients with mNSCLC expressing PD-L1 (≥1%) with no EGFR or ALK genomic tumour aberrations CheckMate 227
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% CheckMate 227

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Selpercatinib - Single arm Treatment for adult patients who require systemic therapy following prior treatment with immunotherapy and/or platinum-based ChT LIBRETTO-001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer RET fusion-positive LIBRETTO-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Sacituzumab govitecan - Single arm (Phase I/II) Treatment for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease IMMU-132-01
    Breast Cancer
    		 Breast Cancer Triple-negative IMMU-132-01

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Neratinib Capecitabine Lapatinib plus capecitabine Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic setting NALA
    Breast Cancer
    		 Breast Cancer HER2+ NALA

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      1
    Selpercatinib - Single arm Treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 3)
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant LIBRETTO-001 (Cohort 3)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Selpercatinib - Single arm As monotherapy for the treatment of adult and adolescents ≥12 years of age with advanced RET-mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 4)
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant LIBRETTO-001 (Cohort 4)

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Ripretinib - Placebo (Crossover allowed) EMA: Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. FDA: Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. INVICTUS
    Sarcoma
    		 GIST - INVICTUS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.